Fibroblast growth factors and their receptors in cancer

被引：443

作者：

Wesche, Jorgen ^{[1
]}

Haglund, Kaisa

Haugsten, Ellen Margrethe

机构：

[1] Univ Oslo, Fac Med, Ctr Canc Biomed, Oslo, Norway

来源：

BIOCHEMICAL JOURNAL | 2011年 / 437卷

关键词：

cancer; fibroblast growth factor (FGF); fibroblast growth factor receptor (FGFR); receptor tyrosine kinase; signalling; therapy; FGFR4 GLY388ARG POLYMORPHISM; POTENT ANTITUMOR-ACTIVITY; GENOME-WIDE ASSOCIATION; SQUAMOUS-CELL CARCINOMA; MOUSE MAMMARY-TUMORS; PROSTATE-CANCER; MULTIPLE-MYELOMA; TYROSINE KINASE; BLADDER-CANCER; ACTIVATING MUTATIONS;

D O I：

10.1042/BJ20101603

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

FGFs (fibroblast growth factors) and their receptors (FGFRs) play essential roles in tightly regulating cell proliferation, survival, migration and differentiation during development and adult life. Deregulation of FGFR signalling, on the other hand, has been associated with many developmental syndromes, and with human cancer. In cancer, FGFRs have been found to become overactivated by several mechanisms, including gene amplification, chromosomal translocation and mutations. FGFR alterations are detected in a variety of human cancers, such as breast, bladder, prostate, endometrial and lung cancers, as well as haematological malignancies. Accumulating evidence indicates that FGFs and FGFRs may act in an oncogenic fashion to promote multiple steps of cancer progression by inducing mitogenic and survival signals, as well as promoting epithelial mesenchymal transition, invasion and tumour angiogenesis. Therapeutic strategies targeting FGFs and FGFRs in human cancer are therefore currently being explored. In the present review we will give an overview of FGF signalling, the main FGFR alterations found in human cancer to date, how they may contribute to specific cancer types and strategies for therapeutic intervention.

引用

页码：199 / 213

页数：15

共 194 条

[31]

d'Avis PY, 1998, CELL GROWTH DIFFER, V9, P71

[32] Similar expression to FGF (Sef) inhibits fibroblast growth factor-induced tumourigenic behaviour in prostate cancer cells and is downregulated in aggressive clinical disease [J].

Darby, S. ;

Murphy, T. ;

Thomas, H. ;

Robson, C. N. ;

Leung, H. Y. ;

Mathers, M. E. ;

Gnanapragasam, V. J. .

BRITISH JOURNAL OF CANCER, 2009, 101 (11) :1891-1899

[33] Somatic mutations of the protein kinase gene family in human lung cancer [J].

Davies, H ;

Hunter, C ;

Smith, R ;

Stephens, P ;

Greenman, C ;

Bignell, G ;

Teague, B ;

Butler, A ;

Edkins, S ;

Stevens, C ;

Parker, A ;

O'Meara, S ;

Avis, T ;

Barthorpe, S ;

Brackenbury, L ;

Buck, G ;

Clements, B ;

Cole, J ;

Dicks, E ;

Edwards, K ;

Forbes, S ;

Gorton, M ;

Gray, K ;

Halliday, K ;

Harrison, R ;

Hills, K ;

Hinton, J ;

Jones, D ;

Kosmidou, V ;

Laman, R ;

Lugg, R ;

Menzies, A ;

Perry, J ;

Petty, R ;

Raine, K ;

Shepherd, R ;

Small, A ;

Solomon, H ;

Stephens, Y ;

Tofts, C ;

Varian, J ;

Webb, A ;

West, S ;

Widaa, S ;

Yates, A ;

Brasseur, F ;

Cooper, CS ;

Flanagan, AM ;

Green, A ;

Knowles, M .

CANCER RESEARCH, 2005, 65 (17) :7591-7595

[34] Comparative pre-clinical evaluation of receptor tyrosine kinase inhibitors for the treatment of multiple myeloma [J].

de Brito, Luis R. ;

Batey, Mike A. ;

Zhao, Yan ;

Squires, Matt S. ;

Maitland, Helen ;

Leung, Hing Y. ;

Hall, Andrew G. ;

Jackson, Graham ;

Newell, David R. ;

Irving, Julie A. E. .

LEUKEMIA RESEARCH, 2011, 35 (09) :1233-1240

[35] Molecular and cellular biology of rhabdomyosarcoma [J].

De Giovanni, Carla ;

Landuzzi, Lorena ;

Nicoletti, Giordano ;

Lollini, Pier-Luigi ;

Nanni, Patrizia .

FUTURE ONCOLOGY, 2009, 5 (09) :1449-1475

[36] Decreased expression of keratinocyte growth factor receptor in a subset of human transitional cell bladder carcinomas [J].

deMedina, SGD ;

Chopin, D ;

ElMarjou, A ;

Delouvee, A ;

LaRochelle, WJ ;

Hoznek, A ;

Abbou, C ;

Aaronson, SA ;

Thiery, JP ;

Radvanyi, F .

ONCOGENE, 1997, 14 (03) :323-330

[37] The t(8;22) in chronic myeloid leukemia fuses BCR to FGFR1: transforming activity and specific inhibition of FGFR1 fusion proteins [J].

Demiroglu, A ;

Steer, EJ ;

Heath, C ;

Taylor, K ;

Bentley, M ;

Allen, SL ;

Koduru, P ;

Brody, JP ;

Hawson, G ;

Rodwell, R ;

Doody, ML ;

Carnicero, F ;

Reiter, A ;

Goldman, JM ;

Melo, JV ;

Cross, NCP .

BLOOD, 2001, 98 (13) :3778-3783

[38] Targeting FGF19 inhibits tumor growth in colon cancer xenograft and FGF19 transgenic hepatocellular carcinoma models [J].

Desnoyers, Lr ;

Pai, R. ;

Ferrando, Re ;

Hotzel, K. ;

Le, T. ;

Ross, J. ;

Carano, R. ;

D'Souza, A. ;

Qing, J. ;

Mohtashemi, I. ;

Ashkenazi, A. ;

French, Dm .

ONCOGENE, 2008, 27 (01) :85-97

[39] Somatic mutations affect key pathways in lung adenocarcinoma [J].

Ding, Li ;

Getz, Gad ;

Wheeler, David A. ;

Mardis, Elaine R. ;

McLellan, Michael D. ;

Cibulskis, Kristian ;

Sougnez, Carrie ;

Greulich, Heidi ;

Muzny, Donna M. ;

Morgan, Margaret B. ;

Fulton, Lucinda ;

Fulton, Robert S. ;

Zhang, Qunyuan ;

Wendl, Michael C. ;

Lawrence, Michael S. ;

Larson, David E. ;

Chen, Ken ;

Dooling, David J. ;

Sabo, Aniko ;

Hawes, Alicia C. ;

Shen, Hua ;

Jhangiani, Shalini N. ;

Lewis, Lora R. ;

Hall, Otis ;

Zhu, Yiming ;

Mathew, Tittu ;

Ren, Yanru ;

Yao, Jiqiang ;

Scherer, Steven E. ;

Clerc, Kerstin ;

Metcalf, Ginger A. ;

Ng, Brian ;

Milosavljevic, Aleksandar ;

Gonzalez-Garay, Manuel L. ;

Osborne, John R. ;

Meyer, Rick ;

Shi, Xiaoqi ;

Tang, Yuzhu ;

Koboldt, Daniel C. ;

Lin, Ling ;

Abbott, Rachel ;

Miner, Tracie L. ;

Pohl, Craig ;

Fewell, Ginger ;

Haipek, Carrie ;

Schmidt, Heather ;

Dunford-Shore, Brian H. ;

Kraja, Aldi ;

Crosby, Seth D. ;

Sawyer, Christopher S. .

NATURE, 2008, 455 (7216) :1069-1075

[40] FGF8 over-expression in prostate cancer is associated with decreased patient survival and persists in androgen independent disease [J].

Dorkin, TJ ;

Robinson, MC ;

Marsh, C ;

Bjartell, A ;

Neal, DE ;

Leung, HY .

ONCOGENE, 1999, 18 (17) :2755-2761

← 1 2 3 4 5 6 7 8 9 10 →